Zai Lab stock rockets 24% on data for lung cancer ADC drug 39m

Zai Lab (NASDAQ:ZLAB) shares shot up 24% in early trading Thursday after the company reported positive results from a Phase 1 study of its antibody drug conjugate ZL-1310 in the treatment of advanced small cell lung cancer.